Volitionrx (VNRX) Capital Expenditures Growth (3y) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 10.17% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 1.81% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2.15% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 0.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.35% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 8.08% |
| 10 | Volitionrx | 101.83 Mn | 99.36 Mn | -1.01 Mn | -73.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -73.34% |
| Jun 30, 2025 | -47.85% |
| Mar 31, 2025 | -75.61% |
| Dec 31, 2024 | -17.35% |
| Sep 30, 2024 | -1.21% |
| Jun 30, 2024 | -56.41% |
| Mar 31, 2024 | -53.08% |
| Dec 31, 2023 | -37.76% |
| Sep 30, 2023 | 111.07% |
| Dec 31, 2022 | 79.81% |
| Sep 30, 2022 | 66.95% |
| Jun 30, 2022 | 85.08% |
| Mar 31, 2022 | 46.00% |
| Dec 31, 2021 | 45.61% |
| Sep 30, 2021 | 64.41% |
| Jun 30, 2021 | 47.02% |
| Mar 31, 2021 | 99.82% |
| Dec 31, 2020 | 145.75% |
| Sep 30, 2020 | -7.85% |
| Jun 30, 2020 | 37.12% |
| Mar 31, 2020 | -33.48% |
| Dec 31, 2019 | -35.10% |
| Sep 30, 2019 | -98.55% |
| Dec 31, 2018 | -145.00% |
| Sep 30, 2018 | -130.75% |
| Jun 30, 2018 | -84.07% |
| Mar 31, 2018 | 49.10% |
| Dec 31, 2017 | 150.88% |
| Sep 30, 2017 | -25.12% |
| Jun 30, 2017 | 132.61% |
| Mar 31, 2017 | 264.49% |
| Dec 31, 2016 | 6,779.98% |
| Sep 30, 2016 | 2,661.24% |
| Dec 31, 2015 | -21.32% |
| Sep 30, 2015 | 131.45% |
| Jun 30, 2015 | 9.66% |
| Mar 31, 2015 | -21.47% |
| Dec 31, 2014 | -55.08% |
| Sep 30, 2014 | 143.20% |
| Jun 30, 2014 | 105.75% |